About 17,378 shares traded. Meridian Bancorp, Inc. (NASDAQ:EBSB) has risen 23.27% since August 11, 2016 and is uptrending. It has outperformed by 14.46% the S&P500.
The stock of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) is a huge mover today! About 605,461 shares traded. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) has declined 49.21% since August 11, 2016 and is downtrending. It has underperformed by 58.02% the S&P500.The move comes after 8 months positive chart setup for the $39.46M company. It was reported on Mar, 20 by Barchart.com. We have $4.34 PT which if reached, will make NASDAQ:PTX worth $3.16M more.
Among 4 analysts covering Pernix Therapeutics (NASDAQ:PTX), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Pernix Therapeutics had 9 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Hold” rating by Brean Capital on Friday, August 12. JMP Securities reinitiated the stock with “Market Outperform” rating in Wednesday, September 9 report. Needham downgraded Pernix Therapeutics Holdings Inc (NASDAQ:PTX) on Friday, March 11 to “Hold” rating. The stock has “Buy” rating by Brean Capital on Friday, March 11. As per Thursday, March 17, the company rating was downgraded by Oppenheimer. The stock has “Strong Buy” rating by Needham on Friday, August 7. Brean Capital maintained Pernix Therapeutics Holdings Inc (NASDAQ:PTX) on Tuesday, February 9 with “Buy” rating. On Friday, August 7 the stock rating was maintained by Brean Capital with “Buy”.
Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The company has market cap of $39.46 million. The Firm focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It currently has negative earnings. It focuses on underserved therapeutic areas, such as central nervous system , including neurology and psychiatry, as well as other specialty therapeutic areas.
Analysts await Pernix Therapeutics Holdings Inc (NASDAQ:PTX) to report earnings on March, 28 after the close.
Analysts await Meridian Bancorp, Inc. (NASDAQ:EBSB) to report earnings on April, 25. They expect $0.20 EPS, up 42.86% or $0.06 from last year’s $0.14 per share. EBSB’s profit will be $10.72M for 23.31 P/E if the $0.20 EPS becomes a reality. After $0.22 actual EPS reported by Meridian Bancorp, Inc. for the previous quarter, Wall Street now forecasts -9.09% negative EPS growth.
Ratings analysis reveals 0 of Meridian Interstate Bancorp’s analysts are positive. Out of 2 Wall Street analysts rating Meridian Interstate Bancorp, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $13.75 while the high is $15.25. The stock’s average target of $14.50 is -22.25% below today’s ($18.65) share price. EBSB was included in 3 notes of analysts from September 30, 2015. The stock of Meridian Bancorp, Inc. (NASDAQ:EBSB) earned “Neutral” rating by Compass Point on Friday, November 18. The stock has “Market Perform” rating by Hovde Group on Wednesday, September 30.
Salzhauer Michael holds 1.97% of its portfolio in Meridian Bancorp, Inc. for 211,046 shares. Ejf Capital Llc owns 1.00 million shares or 1.41% of their US portfolio. Moreover, Stieven Capital Advisors L.P. has 1.38% invested in the company for 370,424 shares. The New Hampshire-based Pax World Management Llc has invested 0.93% in the stock. Monarch Partners Asset Management Llc, a Massachusetts-based fund reported 512,866 shares.
